Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Moderna, Inc.

< Previous 1 2 3 4 5 Next >
Moderna Announces Advances Across Its Industry-Leading mRNA Pipeline and Provides Business Update
From Moderna, Inc.
Via AccessWire
Tickers MRNA
Moderna and Carisma Establish Collaboration to Develop in vivo Engineered Chimeric Antigen Receptor Monocytes (CAR-M) for Oncology
From Moderna, Inc.
Via AccessWire
Tickers MRNA
Moderna Announces First Participant Dosed in Phase 1 Study of its mRNA Epstein-Barr Virus (EBV) Vaccine
From Moderna, Inc.
Via AccessWire
Tickers MRNA
Moderna to Present at the Goldman Sachs 14th Annual Healthcare CEOs Unscripted Conference
From Moderna, Inc.
Via AccessWire
Tickers MRNA
Moderna to Provide Business and Pipeline Updates at the 2022 J.P. Morgan Healthcare Conference
From Moderna, Inc.
Via AccessWire
Tickers MRNA
Moderna Announces Supply Agreement with South Korea for Additional 20 Million Doses of Moderna’s COVID-19 Vaccine or Updated Booster Candidate in 2022
From Moderna, Inc.
Via AccessWire
Tickers MRNA
Moderna Announces Switzerland Exercises its Option to Purchase Seven Million Additional Doses of Moderna's COVID-19 Booster Vaccine in 2022
From Moderna, Inc.
Via AccessWire
Tickers MRNA
Moderna Announces Preliminary Booster Data and Updates Strategy to Address Omicron Variant
From Moderna, Inc.
Via Business Wire
Tickers MRNA
Moderna and Australia Announce Collaboration to Bring mRNA Manufacturing to Australia
From Moderna, Inc.
Via Business Wire
Tickers MRNA
Moderna Announces Additional 20 Million Doses of COVID-19 Vaccine to COVAX for Supply in 2021 and New Additional Supply Agreement for 2022
From Moderna, Inc.
Via Business Wire
Tickers MRNA
Moderna Announces Positive Interim Phase 1 Data for mRNA Flu Vaccine and Provides Program Update
From Moderna, Inc.
Via Business Wire
Tickers MRNA
Moderna to Host Conference Call on Phase 1 Interim Analysis for mRNA Flu Vaccine on Friday, December 10
From Moderna, Inc.
Via Business Wire
Tickers MRNA
Moderna Launches AI Academy in Partnership with Carnegie Mellon University
From Moderna, Inc.
Via Business Wire
Tickers MRNA
Moderna Announces Supply Agreement with the UK for Additional 60 Million Doses of Moderna’s COVID-19 Vaccine in 2022 and 2023
From Moderna, Inc.
Via Business Wire
Tickers MRNA
Moderna to Present at Upcoming Investor Conferences in December 2021
From Moderna, Inc.
Via Business Wire
Tickers MRNA
U.S. CDC Advisory Committee on Immunization Practices Recommends Booster Vaccination with Moderna’s COVID-19 Vaccine
From Moderna, Inc.
Via Business Wire
Tickers MRNA
Moderna Announces FDA Authorization of Booster Dose of COVID-19 Vaccine in the U.S. for Adults 18 Years and Older
From Moderna, Inc.
Via Business Wire
Tickers MRNA
Moderna Announces First Participant Dosed in Phase 2/3 Study of its mRNA Respiratory Syncytial Virus (RSV) Vaccine
From Moderna, Inc.
Via Business Wire
Tickers MRNA
Moderna Tops BioSpace’s 2022 Best Places to Work Ranking in Large Employer Category
From Moderna, Inc.
Via Business Wire
Tickers MRNA
Moderna Files for Authorization of its COVID-19 Vaccine with Health Canada to Include Children Ages 6-11 Years
From Moderna, Inc.
Via Business Wire
Tickers MRNA
Moderna Announces European Union and European Economic Area Countries to Donate More than 70 Million Doses of Moderna COVID-19 Vaccine to COVAX in 2021 to Help End COVID-19 Pandemic in Low Income Countries
From Moderna, Inc.
Via Business Wire
Tickers MRNA
Health Canada Authorizes Booster Dose of Moderna’s COVID-19 Vaccine in Individuals 18 Years of Age and Older
From Moderna, Inc.
Via Business Wire
Tickers MRNA
Moderna Announces Positive Data from Phase 2 Study of mRNA VEGF-A Therapeutic in Patients Undergoing Coronary Artery Bypass Grafting Surgery
From Moderna, Inc.
Via Business Wire
Tickers MRNA
Moderna Announces Presentation of Interim Data from Phase 1 Study of mRNA Triplet Program at 2021 SITC Annual Meeting
From Moderna, Inc.
Via Business Wire
Tickers MRNA
Moderna Files to Expand the Conditional Marketing Authorization for its COVID-19 Vaccine in the European Union to Include Children Ages 6-11 Years
From Moderna, Inc.
Via Business Wire
Tickers MRNA
Moderna Reports Third Quarter Fiscal Year 2021 Financial Results and Provides Business Updates
From Moderna, Inc.
Via Business Wire
Tickers MRNA
Moderna and Metagenomi Establish Collaboration to Develop Next-Generation In Vivo Gene Editing Therapeutics
From Moderna, Inc.
Via Business Wire
Tickers MRNA
Moderna Announces Pledge to Achieve Net-Zero Carbon Emissions Globally by 2030
From Moderna, Inc.
Via Business Wire
Tickers MRNA
Moderna Provides Update on Timing of U.S. Emergency Use Authorization of its COVID-19 Vaccine for Adolescents
From Moderna, Inc.
Via Business Wire
Tickers MRNA
Moderna Announces Additional Supply for Q2 2022 of Vaccine for COVAX To Help End COVID-19 Pandemic in Lowest Income Countries
From Moderna, Inc.
Via Business Wire
Tickers MRNA
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.